News >

Biosimilars Poised to Drive Down Treatment Costs in Oncology

Ellie Leick
Published: Monday, Dec 23, 2019

Julie R. Gralow, MD, clinical director of Breast Medical Oncology at Seattle Cancer Care Alliance and professor of Medical Oncology at University of Washington School of Medicine

Julie R. Gralow, MD

With several biosimilars approved by the FDA, these agents are now beginning to be used in clinical practice in place of the reference products, explained Julie R. Gralow, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication